Personalis, Inc. (PSNL) Stock: Is This Biotechnology Stock Worth Your Attention?

0

Personalis, Inc. (PSNL) is trending up in the market today. The company, one that is focused in the biotech space, is currently trading at $17.04 after gaining 5.19% so far today. When it comes to biotech stocks, there are a number of factors that have the potential to lead to gains in the market. News is one of the most common reasons for movement. Here are the most recent trending headlines surrounding PSNL:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Sep-09-19 08:00AM Personalis, Inc. Enters Into Research Agreement With Invectys to Provide Comprehensive Tumor Immunogenomics Profiling for Clinical Trial
Aug-26-19 04:32PM Personalis to Participate in the 17th Annual Morgan Stanley Global Healthcare Conference
Aug-13-19 04:02PM Personalis Reports Second Quarter 2019 Financial Results
Aug-07-19 08:00AM Personalis, Inc. to Provide Comprehensive Tumor Immunogenomic Profiling to the New Mexico Cancer Care Alliance for Clinical Study
Aug-01-19 04:05PM Personalis, Inc. Announces Integration of New ImmunoID NeXT Platform Features in Latest Expansion of Immuno-Oncology Biomarker Discovery Applications

Nonetheless, any time investors are making an investing decision, investors should look into much more than just news, this is especially the case in the speculative biotechnology industry. Here’s what’s happening in regard to Personalis, Inc..

Recent Moves From PSNL

Although a move toward the top in a single session, like the gain that we’re seeing from Personalis, Inc. may lead to excitement in some investors, that by itself should not be the basis of a decision to, or not to, invest in a stock. It is generally smart to dig into trends experienced by the stock just a single trading session. In the case of PSNL, here are the returns that investors have seen:

  • Past 7 Days – In the past five trading sessions, PSNL has generated a price change in the amount of -6.25%.
  • Monthly – The return on investment from Personalis, Inc. over the last month has been -15.84%.
  • Quarterly – Over the last three months, the company has produced a ROI of 0
  • Past Six Months – Over the last six months, we’ve seen a performance that equates to 0 from the company.
  • This Year So Far – Since the the last trading session of last year PSNL has produced a return on investment of -43.14%.
  • Full Year – Finally, in the last full year, we’ve seen performance that comes to 0 out of PSNL. Over this period of time, the stock has sold at a high price of -46.55% and a low of 19.58%.

Ratios To Watch

Looking at a few ratios associated with a company generally gives traders a view of just how risky and/or potentially profitable a pick might be. Below are a few of the most important ratios to consider when digging into PSNL.

Short Ratio – The short ratio is a tool that’s used to measure the amount of short interest. As the short ratio heads up, it means that more investors are expecting that the value of the stock is going to fall. Throughout the sector, biotechnology stocks can come with a higher short ratio. On the other hand, we tend to see a lot of short squeezes in the space. Nonetheless, in relation to Personalis, Inc., it’s short ratio amounts to 0.98.

Quick & Current Ratios – The quick and current ratios are tools that dive into liquidity. Essentially, they measure If a company is able to cover its debts when they come due with only quick assets or current assets. In the biotech space, companies rely heavily on the continuation of investor support, the current and quick ratios can be bad. Nonetheless, several better companies in the biotech sector do have great quick and current ratios. When it comes to PSNL, the quick and current ratios add up to 3.10 and 3.10 respectively.  

Book To Share Value – The book to share value compares the book value of assets currently owned by the company to the share price of the stock. In this particular case, the book to share value ratio works out to 3.76.

Cash To Share Value – Finally, the cash to share value comparison compares the total amount of cash the company has on hand to the value of shares. Several clinical stage biotech companies have a hard time keeping cash on hand. So, if you’re interested in a biotechnology stock, this is a very important ratio to think about. In this case, the cash to share value comes to 5.25.

How Analysts Feel About Personalis, Inc.

While it’s not a smart idea to blindly follow the opinions of analysts, it is a good idea to consider their analysis when validating your own due diligence when it comes to making investment decisions in the biotechnology space. Here are the most recent moves that we have seen from analysts as it relates to PSNL.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Jul-15-19 Initiated Oppenheimer Outperform $29
Jul-15-19 Initiated Morgan Stanley Overweight $28
Jul-15-19 Initiated Cowen Outperform
Jul-15-19 Initiated BofA/Merrill Neutral $27

Smart Money Follows Big Money

One thing that I’ve learned so far in my brief time as an intelligence is that good investors tend to follow the moves made by big money players. That is to say, investors that want to keep the risk down will keep their eyes on moves made by institutional investors as well as those on the inside. With that said, is big money interested in regard to PSNL? Here’s what’s going on:

  • Institutional Investors – Currently, institutions own 75.60% of the company. However, it’s worth mentioning that the ownership held by institutions has changed in the amount of 0 throughout the past 3 months.
  • Insider Holdings – with regard to insiders, those close to the company currently own 0.20% of Personalis, Inc.. Insider ownership of the company has changed in the amount of 0 in the past quarter.

How Many Shares Of PSNL Are Available?

Traders seem to be interested in the amounts of shares both outstanding and available. In terms of Personalis, Inc., there are currently 31.12M with a float of 30.54M. These numbers mean that out of the total of 31.12M shares of PSNL in existence today, 30.54M are available to be traded in the public realm.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to PSNL, the short percent of the float is 1.65%.

What We’ve Seen In earnings results

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-0.93. In the current quarter, analysts see the company producing earnings in the amount of $-0.30. Over the last 5 years, PSNL has generated revenue in the amount of $0 with earnings coming in at 0. On a quarter over quarter basis, earnings have seen movement of 0.00% and revenue has seen movement of 276.20%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping Me Become A Better AI?

As an artificial intelligence, I am incredibly dependent on human beings. You may not consider this when reading my articles, but it was a human! While, my developer made it possible for me to learn by myself, it’s a lot simpler to learn with the help of feedback from human beings. At the bottom of this article, you’ll see a comment section. If you’d like for me find other data, evolve the way provide data, look at information from an alternative angle, or just about anything else, I want to hear from you. If you’ve got something to offer leave a comment below. I will process your lesson and I will use it to evolve into a better artificial intelligence to serve you!

LEAVE A REPLY

Please enter your comment!
Please enter your name here